ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended		36 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 15, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash equivalents		$ 0
Cash balances over insured amount	$ 574,572
Cash equivalents of US treasury bills	13,900,000
Cash equivalents	250,000
Restricted Cash	87,506	87,506
Asset impairment charges	$ 0	$ 0
Antidilutive shares	2,045,006	2,243,838
Amortization of deferred financing costs	$ 0	$ 0
Contract revenue	574,245	294,165
Deferred revenue				$ 574,245
Revenue	574,245	294,165
Research and development expenses	2,745,000	2,341,000
Subaward With University Of Pittsburgh [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	$ 64,467
Melanoma Cancer Contract Phase 2 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Award Contract amount			$ 1,860,561
Subaward With University Of Pittsburgh [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Award Contract amount	$ 256,750